STOCKHOLM--(BUSINESS WIRE)--SciBase has signed a distribution agreement for Switzerland with CDP SWISS AG. The sales and marketing effort of SciBase’s melanoma detection product Nevisense will initially be focused on the nearly 400 dermatologists that work in private clinics in Switzerland.
Switzerland is the country in Europe with the highest prevalence of malignant melanoma. Each year approximately 2,500 new cases of the disease are diagnosed, which makes the market potentially very interesting for SciBase. Approximately 70 percent of the 500 dermatologists in Switzerland operate full time at private clinics.
- Switzerland is one of Europe’s smaller markets, but we believe that there is good potential there. A high proportion of skin cancer screenings take place in private clinics – clinics that are usually more open to new methods. With CDP SWISS AG we have a distributor with well-established contacts right into our target customer and they have a good track record of similar products, says Simon Grant, CEO of SciBase.
By signing an agreement with one of the premier distributors of medical devices for dermatologists, SciBase will firmly establish Nevisense on the Swiss market. While the focus of CDP SWISS AG will be private dermatologists, they will also address the nine hospital-based public clinics as these clinics often evaluate products and publish results – and this can in turn influence the private clinics.
- We are very pleased to be able to represent SciBase and Nevisense in Switzerland. With Nevisense, the health care system gains access to an objective tool which helps to identify early stage malignant melanoma that in the end might save lives. There is a great interest in methods to improve diagnosis and many Swiss Doctors have heard of Nevisense from their German colleagues, says Falk Dörstling, CEO of CDP SWISS AG.
CDP SWISS AG specialize on medical technology products for dermatologists, with a focus on laser-based products. They offer a complete coverage of Switzerland. The Company has been active for 10 years and has shown strong growth from the start, thanks to their strong customer relationships.
About Skin Cancer
Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to age 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.
This information was brought to you by Cision http://news.cision.com
SciBase
Simon Grant, CEO
Phone: +46 72 887 43 99
Email: simon.grant@scibase.com
